Skip to main content
Fig. 2 | BMC Public Health

Fig. 2

From: A cost-benefit analysis of a proposed overseas refugee latent tuberculosis infection screening and treatment program

Fig. 2

Total Cost Incurred with Two Programs for Identifying and Treating LTBI in 100,000 U.S. -Bound Refugees. LTBI = latent tuberculosis infection; TST = tuberculin skin test; U.S.  = United States. With no overseas screening, all screening and treatment for LTBI takes place in the U.S. With overseas screening, initial screening takes place overseas and TST positive refugees are offered treatment overseas. Costs incurred overseas include the TST, 12 weeks of once-weekly rifapentine and isoniazid, and labor to administer the medications. Costs incurred domestically include the TST, 12 weeks of once-weekly rifapentine and isoniazid, labor to administer the medications, and treatment of active TB patients

Back to article page